We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Epizyme Receives Milestone from Glaxo for Lymphoma Drug
Read MoreHide Full Article
Epizyme, Inc. announced that the company has earned a milestone payment worth $6 million from GlaxoSmithKline (GSK - Free Report) .
The payment was triggered by Glaxo’s initiation of a phase I study on GSK3326595 (formerly EPZ015938). The company initiated a phase I dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in patients with solid tumors and non-Hodgkin lymphoma.
Epizyme had licensed the candidate to Glaxo. Under the terms of the collaboration agreement, Epizyme granted exclusive worldwide license rights to Glaxo to methyltransferase inhibitors directed at three targets.
While Epizyme was primarily responsible for pre-clinical research, Glaxo is responsible for subsequent research, development and commercialization of the three programs. Epizyme discovered and optimized compounds targeting three methyltransferases, including PRMT5 but Glaxo holds worldwide rights to all three programs. Among these, GSK3326595 is the first to enter the clinical stage.
To date, Epizyme has earned $59 million in up-front, research, and milestone payments. The company is entitled to receive up to an additional $617 million from Glaxo on the achievement of all milestones for all the three programs.
Moreover, Epizyme is eligible to receive up to double-digit royalties on worldwide net sales of the collaboration products.
With no approved product in its kitty as of yet, Epizyme is highly dependent on its collaboration partners for top-line growth. The company’s pipeline is still early stage and several years from commercialization.
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Epizyme Receives Milestone from Glaxo for Lymphoma Drug
Epizyme, Inc. announced that the company has earned a milestone payment worth $6 million from GlaxoSmithKline (GSK - Free Report) .
The payment was triggered by Glaxo’s initiation of a phase I study on GSK3326595 (formerly EPZ015938). The company initiated a phase I dose-escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in patients with solid tumors and non-Hodgkin lymphoma.
Epizyme had licensed the candidate to Glaxo. Under the terms of the collaboration agreement, Epizyme granted exclusive worldwide license rights to Glaxo to methyltransferase inhibitors directed at three targets.
While Epizyme was primarily responsible for pre-clinical research, Glaxo is responsible for subsequent research, development and commercialization of the three programs. Epizyme discovered and optimized compounds targeting three methyltransferases, including PRMT5 but Glaxo holds worldwide rights to all three programs. Among these, GSK3326595 is the first to enter the clinical stage.
EPIZYME INC Price
EPIZYME INC Price | EPIZYME INC Quote
To date, Epizyme has earned $59 million in up-front, research, and milestone payments. The company is entitled to receive up to an additional $617 million from Glaxo on the achievement of all milestones for all the three programs.
Moreover, Epizyme is eligible to receive up to double-digit royalties on worldwide net sales of the collaboration products.
With no approved product in its kitty as of yet, Epizyme is highly dependent on its collaboration partners for top-line growth. The company’s pipeline is still early stage and several years from commercialization.
Epizyme currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Ligand Pharmaceuticals (LGND - Free Report) and Pacira Pharmaceuticals (PCRX - Free Report) . Both these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>